Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (531-540 of 636) with videos related to

Pageof 64
Sort By:
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|June 5, 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trialFreddy Abnousi, Vandana Sundaram, Celina M Yong, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Circulation. Arrhythmia and Electrophysiology|April 17, 2020
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AFBenjamin A Steinberg, DaJuanicia N Holmes, Karen Pieper, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Journal of the American College of Cardiology|September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 DiabetesBrendon L Neuen, John W Ostrominski, Brian Claggett, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Pageof 64

Showing results (531-540 of 636) with videos related to

Sort By:
Pageof 64
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|June 5, 2017
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trialFreddy Abnousi, Vandana Sundaram, Celina M Yong, et al.
Lancet (London, England)|September 2, 2024
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsMikhail N Kosiborod, John Deanfield, Richard Pratley, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
Circulation. Arrhythmia and Electrophysiology|April 17, 2020
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AFBenjamin A Steinberg, DaJuanicia N Holmes, Karen Pieper, et al.
Journal of Diabetes Research|June 9, 2022
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE TrialTamara K Young, Nigel D Toussaint, Gian Luca Di Tanna, et al.
Journal of the American College of Cardiology|September 1, 2024
Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 DiabetesBrendon L Neuen, John W Ostrominski, Brian Claggett, et al.
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Pageof 64